Related Experiment Video
Updated: May 28, 2026

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography
Philipp Pichler1, Emel Pichler-Cetin, Markus Vertesich
1Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria. philipp.pichler@meduniwien.ac.at
Insights
Ivabradine effectively lowers heart rate for coronary CT angiography, showing a significantly smaller decrease in systolic blood pressure compared to metoprolol. This makes ivabradine a potentially safer option for patients undergoing this imaging procedure.
Area of Science:
- Cardiology
- Radiology
- Pharmacology
Background:
- Heart rate (HR) and image quality in coronary computed tomography angiography (CCTA) are correlated.
- Beta-blockers are commonly used to reduce HR but can negatively impact cardiac contractility.
- Ivabradine is a selective HR-lowering agent that does not affect cardiac contractility or conduction.
Purpose of the Study:
- To compare the efficacy and safety of ivabradine versus metoprolol for HR reduction prior to CCTA.
- To assess the impact of these agents on blood pressure (BP) during CCTA premedication.
Main Methods:
- A randomized trial involving 120 patients undergoing CCTA.
- Patients received either oral ivabradine (15 mg) or metoprolol (50 mg) as premedication.
- HR and BP were measured before and after premedication; comparisons were made between groups.
Main Results:
- Both ivabradine and metoprolol significantly reduced HR and diastolic BP, with no significant difference between groups.
- Ivabradine resulted in a significantly smaller decrease in systolic BP compared to metoprolol (p <0.001).
- In patients on long-term beta-blockers, ivabradine achieved greater HR reduction and less systolic BP decrease than metoprolol.
Conclusions:
- Ivabradine provides sufficient HR reduction for CCTA.
- Ivabradine demonstrates a superior safety profile regarding systolic BP depression compared to metoprolol.
- Ivabradine is a viable alternative for HR control in CCTA, especially in patients sensitive to BP changes.
Abstract:
Several studies have demonstrated the correlation of heart rate (HR) and image quality in coronary computed tomography angiography. Beta-blocker administration is critical because of its negative inotropic effect. Ivabradine is a selective HR-lowering agent that exclusively inhibits the I(f) current in sinoatrial node cells without having any effect on cardiac contractility or atrioventricular conduction. A total of 120 patients were randomized to oral premedication with ivabradine 15 mg or metoprolol 50 mg. HR and blood pressure (BP) were measured before the administration of premedication and immediately before coronary computed tomographic angiography. The mean time between premedication administration and follow-up was 108 ± 21.5 minutes for ivabradine and 110 ± 22.2 minutes for metoprolol (p = NS). When comparing groups, there were no significant differences in reduction of HR (-11.83 ± 8.6 vs -13.20 ± 7.8 beats/min, p = NS) and diastolic BP (-5.05 ± 14.2 mm Hg vs -4.08 ± 10.8 mm Hg, p = NS), whereas the decrease of systolic BP was significantly lower in patients who received ivabradine compared to those in the metoprolol group (-3.95 ± 13.6 vs -13.65 ± 17.3 mm Hg, p <0.001). In the subgroup of patients who were receiving long-term β-blocker therapy, significantly stronger HR reduction was achieved with ivabradine (-13.19 ± 5.4 vs -10.04 ± 6.0 beats/min, p <0.05), while the decrease in systolic BP was less (-2.00 ± 13.6 vs -15.04 ± 20.8 mm Hg, p <0.05) compared to metoprolol. In conclusion, ivabradine decreases HR before coronary computed tomographic angiography sufficiently, with significantly less depression of systolic BP compared to metoprolol.
Related Concept Videos
Imaging Studies for Cardiovascular System V: CT
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure Drugs: β-Blockers
